This course will summarize Breast Cancer Science from the following abstracts:
- First 2-Year Results of the Multicenter, Randomized IMRT-MC2 Trial (MINT): Intensity-Modulated Radiotherapy with Simultaneous Integrated Boost Versus 3-D-Conformal Radiotherapy with Consecutive Boost for Breast Cancer Patients
- Reconstruction Outcomes in a Multi-Institution Prospective Phase II Hypofractionated Post-Mastectomy Radiation Therapy trial
- Development and Internal Validation of an NTCP-Model for Acute Coronary Events after Breast Cancer Radiotherapy: First Results of the Medirad Brace Study
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Epigallocatechin-Gallate in the Prevention of Radiation-Induced Dermatitis
- Patient reported experience with treatment modalities and safety of adjuvant breast radiotherapy- First results of the randomized HYPOSIB – study
- Defining the Optimal Dose for 3D-Conformal Accelerated Partial Breast Irradiation (APBI): 10-years Follow Up of a Dose-Escalation Trial
- Heterogeneity in Outcomes Among Women with Clinically Node-Positive Breast Cancer and Axillary Pathologic Complete Response: An Analysis of NSABP B18, B27, B40, and B41
- De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or not to Boost?
The course is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, and all other health professionals involved in the field of radiation oncology.
Upon completion of this activity, learners should be able to do the following:
- Summarize the data from top scoring breast cancer abstracts from the 2020 ASTRO meeting.
- Identify potential ways to appropriately optimize and de-intensify radiation therapy for breast cancer without compromising outcomes.
- Develop tools to predict patient outcomes and toxicity of treatment.
- Describe patient perspectives on radiation treatment for breast cancer to improve quality of care.
Rachel Blitzblau, MD, PhD is employed by Duke University and has no other disclosures to declare.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.